Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05028452
Other study ID # Carer eSupport
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 17, 2023
Est. completion date September 30, 2023

Study information

Verified date February 2024
Source Uppsala University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Informal caregivers to patients with head and neck cancer report that they are unprepared for caregiving, that they experience a high caregiver burden and a deteriorated health. The aim is to develop an internet based intervention for informal caregivers of individuals with head and neck cancer and evaluate the feasibility and acceptability of the intervention. The internet based intervention (Carer eSupport) will be based on scientific evidence, established theoretical frameworks and focus groups with caregivers and health care professionals. The feasibility and acceptability of Carer eSupport will be evaluated by 30 caregivers who will have access to Carer eSupport during one months. The feasibility and acceptability of Carer eSupport will be evaluated with quantitative and qualitative data.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date September 30, 2023
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informal caregivers (defined by the patients) to patients with head and neck cancer who are about to start treatment, undergoing treatment or have completed treatment within the past month. Exclusion Criteria: - Confusion or dementia, inability to understand, speak or read Swedish.

Study Design


Intervention

Other:
Internet based support
Carer eSupport is designed to prepare informal caregivers for caregiving, to decrease caregiver burden and prevent a deteriorated health.

Locations

Country Name City State
Sweden Sahlgrenska university hospital Göteborg Västra Götaland
Sweden Örebro University Hospital Örebro Blekinge Län
Sweden Norrland University Hospital Umeå Västerbottens Län
Sweden Uppsala university hospital Uppsala Uppsala Län

Sponsors (6)

Lead Sponsor Collaborator
Uppsala University Region Örebro County, Region Västerbotten, Swedish Cancer Society, The Swedish Research Council, Uppsala University Hospital

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inclusion rate The proportion of caregivers who give informed consent for participation 4 months
Primary Utilization of Carer eSupport The proportion of included caregivers who take use of Carer eSupport 2 months
Primary Attrition The proportion of included caregivers who withdraw from the study 3 months
Primary Completion of questionnaires The proportion of included caregivers who complete questionnaires 3 months
Primary Perceived feasibility Qualitative data from semi-structured individual interviews exploring perceived feasibility of Carer eSupport. Within 1 months after completion of testing Carer eSupport.
Primary Perceived acceptability Qualitative data from semi-structured individual interviews exploring perceived acceptability of Carer eSupport. Within 1 months after completion of testing Carer eSupport.
Secondary The Preparedness for caregiving scale A brief 8-item self-report measure assessing preparedness for caregiving, a potential primary outcome in a future randomized controlled trial. Assessed at baseline and at 1 months after access to Carer eSupport
Secondary Caregiver´s burden scale A 22-item self-report measure assessing caregiver burden, a potential primary outcome in a future randomized controlled trial. Assessed at baseline and at 1 months after access to Carer eSupport.
Secondary Short Form Health Survey (SF-36), v2. A 36-item self-report measure assessing self-perceived health, a potential secondary outcome in a future randomized controlled trial. Assessed at baseline and at 1 months after access to Carer eSupport.
Secondary The Depression Anxiety Stress Scale-21 A 21-item self-report measure assessing depression, anxiety, and stress, a potential secondary outcome in a future randomized controlled trial. Assessed at baseline and at 1 months after access to Carer eSupport.
Secondary The Multidimensional fatigue inventory A 20-item self-report measure assessing five dimensions of fatigue, a potential secondary outcome in a future randomized controlled trial. Assessed at baseline and at 1 months after access to Carer eSupport.
See also
  Status Clinical Trial Phase
Recruiting NCT05808920 - The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03997643 - Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT04700475 - Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients. N/A
Withdrawn NCT04058145 - AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02572869 - Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT05073809 - Photoacoustic Imaging of Head and Neck Tumours
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Active, not recruiting NCT03651570 - Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study N/A
Recruiting NCT04930432 - Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Terminated NCT03843554 - Commensal Oral Microbiota in Head and Neck Cancer N/A
Recruiting NCT05915572 - Mulligan Technique on Shoulder Dysfunction N/A
Completed NCT05897983 - Tens and Rocabado Exercises on TMJ Dysfunction N/A
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Withdrawn NCT05263648 - Virtual Reality Software to Reduce Stress in Cancer Patients N/A
Withdrawn NCT03238638 - A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy Phase 2